
Quarterly report 2025-Q4
added 04-25-2026
I-Mab EBITDA 2011-2026 | IMAB
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA I-Mab
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 13.8 M | 12.7 M | 9.8 M | 6.7 M | 1.6 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.8 M | 1.6 M | 8.92 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-6.4 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Coherus BioSciences
CHRS
|
-180 M | $ 1.63 | -4.4 % | $ 191 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
19.5 B | - | - | $ 96.9 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-18.7 M | $ 0.73 | -0.03 % | $ 33.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 7.83 | -5.21 % | $ 214 M | ||
|
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | ||
|
Esperion Therapeutics
ESPR
|
60.4 M | $ 3.12 | - | $ 649 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-11.9 M | - | 0.74 % | $ 768 M | ||
|
Exelixis
EXEL
|
901 M | $ 51.1 | -0.37 % | $ 13.9 B | ||
|
Forte Biosciences
FBRX
|
-70.6 M | $ 23.96 | -2.84 % | $ 310 M | ||
|
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | ||
|
Karyopharm Therapeutics
KPTI
|
-90.4 M | $ 8.9 | 0.56 % | $ 1.08 M | ||
|
AbCellera Biologics
ABCL
|
-199 M | $ 4.4 | -7.76 % | $ 1.31 B | ||
|
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 17.3 | -5.57 % | $ 809 M | ||
|
BioNTech SE
BNTX
|
-1.4 B | $ 91.99 | -0.26 % | $ 22.2 B | ||
|
Compugen Ltd.
CGEN
|
-34.6 M | $ 3.03 | 6.32 % | $ 283 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | ||
|
Gilead Sciences
GILD
|
10.4 B | $ 132.06 | -0.74 % | $ 164 B | ||
|
Genmab A/S
GMAB
|
6.57 B | $ 26.9 | 1.32 % | $ 1.74 B | ||
|
Genprex
GNPX
|
-15.5 M | $ 0.86 | 1.2 % | $ 802 K | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 3.49 | -4.12 % | $ 5.75 M | ||
|
Aeterna Zentaris
AEZS
|
-10.7 M | - | 5.93 % | $ 314 M | ||
|
Grifols, S.A.
GRFS
|
1.19 B | $ 7.79 | 1.04 % | $ 5.29 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Fortress Biotech
FBIO
|
-69.8 M | $ 2.3 | 3.14 % | $ 64.2 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 21.57 | -0.55 % | $ 2.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 9.24 | 36.48 % | $ 264 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K |